Oneview Healthcare (ONE) Q3 2026 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 TU earnings summary
26 Oct, 2026Executive summary
Record Q3 customer acquisition: six new logos, comprising four initial Bedside Hub TV deployments and two Care Experience Platform wins.
Cash at 26 October was €4.2m (A$6.7m); pro forma cash including Tranche 2 of the placement was €8.6m (A$13.7m).
Financial highlights
Q3 net operating cash outflow was €4.757m, versus €2.2m in the corresponding 2025 period; lower customer receipts drove the increase.
Customer receipts were €594k in Q3 and €5.736m year to date; Q3 receipts were affected by delayed annual renewals and the absence of prior-year one-off hardware receipts.
Q3 costs were broadly in line with the corresponding 2025 period; lower staff, product and operating costs offset higher administration and corporate costs.
Outlook and guidance
Target is 8–10 new customer logos by year-end 2026; four Bedside Hub customers and two Care Experience Platform customers have already been added.
Q4 2026 and Q1 2027 are expected to bring stronger receipts and lower operating cash outflows, reflecting annual renewal billing and collections; new Bedside Hub activity is expected to contribute.
Tranche 2 is expected to raise A$7m (~€4.4m), subject to shareholder approval at the 25 November 2026 AGM; approval is described as fully expected.
Latest events from Oneview Healthcare
- Recurring revenue up 13% and gross margin at 70%, with US growth from Bedside Hub launch.ONE
H1 2026 - AI-powered orchestration transforms patient care, driving efficiency and restoring time for clinicians.ONE
Investor presentation - Cash position strengthened by equity raise, with improved operating cash flow and strong sales pipeline.ONE
Q1 2026 TU - 21% revenue growth and AI product launches drive expansion amid margin and regulatory risks.ONE
H2 2025 - Q3 2025 saw higher cash outflow but strong sales momentum and new customer deployments.ONE
Q3 2025 TU - 36% revenue growth, AI innovation, and restructuring set up a stronger H2 2025.ONE
H1 2025 - Baxter partnership expanded to Canada; all AGM resolutions passed with overwhelming support.ONE
AGM 2024 - Recurring revenue up 8% and gross margin at 73%, with US growth driven by Baxter partnership.ONE
H1 2024 - Revenue up 5% to €9.9M, losses widen, but cash and US growth support future expansion.ONE
H2 2024